Use Sativex as an adjunct
when patients’ first-line oral
anti-spasticity medications
are not enough1–3

When to prescribe

Sativex should be
before resorting
to invasive

Sativex is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to MS who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy1

Patients should be offered a 4-week trial of Sativex to assess their response1

Those who achieve a ≥20% improvement in spasticity-related symptoms may continue with treatment1

See how many patients responded to treatment with Sativex

covers the cost of
treatment for the
4-week trial so
the NHS only has
to pay for
patients who find
it effective

Pay-for- responders scheme

NICE re-evaluated Sativex in 2019 and recognised the benefits it can offer to patients2

NICE recommended Sativex in conjunction with GW Pharmaceuticals’ pay-for-responders scheme2


Continued funding for patients who respond to Sativex must be formally agreed at a local level before treatment starts




View the NICE and AWMSG recommendations
on the use of Sativex:



Read the terms and conditions of the pay-for-
responders scheme:


Download the pay-for-responders scheme application forms if you wish to participate in the scheme:



Sativex has limited
contraindications and
requirements for dose





Patients with hypersensitivity to cannabinoids or to any of the excipients1


Patients with any known or suspected history or family history of schizophrenia, or other psychotic illness; history of severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition1


Patients who are breastfeeding1



Patients with significant hepatic or renal impairment


Sativex can be administered to patients with mild hepatic impairment without any dose adjustment1

– Administration to patients with moderate or severe hepatic impairment is not advised due to the lack of information on the potential for accumulation of THC and CBD with chronic dosing1


The effects of Sativex may be exaggerated or prolonged in patients with impaired renal function. Frequent clinical evaluation by a clinician is recommended in these patients1



Elderly patients


No specific studies have been carried out in elderly patients, although patients up to 90 years of age have been included in clinical trials1


As elderly patients may be more prone to develop some CNS adverse reactions, care should be taken in terms of personal safety such as preparation of hot food and drinks1